Clostridium Difficile Infection Treatment Market Next Big Thing | Merck, Baxter International, Sanofi
C Diff Drug Development
A Big Leap for Microbiome Therapeutics
Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability.
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease | MarketScreener
MELBOURNE, Australia, Jan. 17, 2023 -- Immuron Limited , an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic... | January 17, 2023
Discovery of potential phytochemicals as inhibitors of TcdB, a major virulence factors of Clostridioides difficile - PubMed
Clostridioides difficile is a gram-positive bacterium which is associated with different gastrointestinal related infections, and the numbers of cases related to it are continuously increasing in the past few years. Owing to high prevalence and development of resistance towards available anti …
An Exciting Time in CDI: Approvals, Approaches and Anticipation
The therapies for Clostridioides difficile infection (CDI) saw many developments in recent months and there are more exciting things to come.
Effect of polysaccharide derived from dehulled adlay on regulating gut microbiota and inhibiting Clostridioides difficile in an in vitro colonic fermentation model - PubMed
Human body can digest only a few sugars with a low degree of polymerization. The rest of the carbohydrates become food for gastrointestinal symbiotic bacteria, affecting gut microbiota composition and human health. Adlay is a medicinal and food homologous crop. The study aims to determine whether de …
Research seeking to outsmart C. diff achieves sustained 50% decrease in infections across eight hospitals
According to recent research conducted at several member hospitals that are part of Trinity Health and published in Infection Control and Hospital Epidemiology, optimized environmental cleaning is the key to effectively reducing C. diff transmission inside hospitals.
Nifty new tools for microbiome treatment design
Nature Reviews Gastroenterology & Hepatology - The gut microbiome field is shifting from association to modulation. Microbiota-based treatments come in many shapes and sizes, ranging from...
Systematic Design of Adenosine Analogs as Inhibitors of a Clostridioides difficile-Specific DNA Adenine Methyltransferase Required for Normal Sporulation and Persistence
Antivirulence agents targeting endospore-transmitted Clostridioides difficile infections are urgently needed. C. difficile-specific DNA adenine methyltransferase (CamA) is required for efficient sporulation and affects persistence in the colon. The active site of CamA is conserved and …
Treatment efficacy of fecal microbiota-based live biotherapeutics (RBX2660) for the prevention of recurring Clostridioides difficile infection
Treatment efficacy of fecal microbiota-based live biotherapeutics (RBX2660) for the prevention of recurring Clostridioides difficile infection
Reaction to the Historic Approval of RBX2660
RBX2660 is the first ever live microbiota therapeutic approved by the FDA.
Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022
Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Infectious Diseases and Therapy on Twitter
Read the final report from the phase 2b PUNCH CD2 study of RBX2660, an investigational live biotherapeutic to reduce C. difficile infection recurrence, showing 24-month safety and meaningful efficacy for 1 dose v placebo - https://t.co/hyVJ0cABVR#cdiff #microbiome— Infectious Diseases and Therapy (@InfectDis_Ther) December 22, 2022
An insight into the Clostridioides difficile infection-related diarrhea - PubMed
An insight into the Clostridioides difficile infection-related diarrhea
Antimicrobial Activity of Tannic Acid In Vitro and Its Protective Effect on Mice against Clostridioides difficile - PubMed
Clostridioides difficile infection (CDI), recurrently reported as an urgent threat owing to its increased prevalence and mortality, has attracted significant attention. As the use of antibiotics to treat CDI has many limitations, such as high recurrence rate, the need to actively seek and develop ot …
Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection - PubMed
ClinicalTrials.gov: NCT02299570.
Global Microbiome Therapeutics Market Report 2022 - Players Include Evelo Biosciences, Ferring International, Immuron and LNC Therapeutics
Dublin, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Microbiome
FDA PDUFA Date Set for C diff Drug, SER-109
The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.
BiomeBank Continues Growth Trajectory With Over $10M Capital Raise - Business Wire
Oral Microbiome Therapeutic Gets Priority Review for Recurrent C difficile Infection
SER-109 contains purified bacterial spores of multiple Firmicute species obtained from the stool of healthy human donors.
Clostridium Difficile Infections Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
With a Massive CAGR of 25%, Human Microbiome Market Size to surpass US$ 442.37 billion by 2030
Pune, Dec. 09, 2022 (GLOBE NEWSWIRE) -- According to a new market research report titled, “Human Microbiome Market by Product (Probiotics, Prebiotics,...
Nicholas Meyer on Twitter
“#cdiff folks, if you are diagnosed with c-diff then look into enrolling in acurx phase 2 trial. 100% cure rate in phase 2a and showed a microbiome response that has never been seen before in history of c-diff antibiotics”
New Therapeutic Offers Promise for Recurrent C Diff Infection
An easy-to-administer oral biologic kept repeat C difficile infections at bay in a new study.
FDA Approves First Fecal Microbiota Product | FDA
The FDA approved the first fecal microbiota product, Rebyota, for the prevention of recurrence of CDI in adults.
MTIG on Twitter
#MicrobiomeTherapeutics have potential to restore microbial diversity to prevent #CDiff spore germination & disease without the complications of antibiotics. Learn about @Rebiotix, @SeresTX & @VedantaBio's work to develop microbiome therapeutics for CDI: https://t.co/dXa0aXsMUb— MTIG (@MTIG_News) December 6, 2022
FDA Approval of First Fecal Microbiota Product Ensures Safety in Standardization: Ferring Chief Scientific Officer Dr. Elizabeth Garner explains the FDA approval of recurrent C diff treatment RBX2660 provides more than a treatment… https://t.co/yzGZzeZa
FDA Approval of First Fecal Microbiota Product Ensures Safety in Standardization: Ferring Chief Scientific Officer Dr. Elizabeth Garner explains the FDA approval of recurrent C diff treatment RBX2660 provides more than a treatment… https://t.co/yzGZzeZaWR #cdiff #cdi #fmt— Dave Roberts (@CDifficile1) December 8, 2022
FDA Greenlights First Fecal Microbiota Product | MedPage Today
Rebyota approved for preventing recurrence of C. difficile infection
Expanding Government Assistance is Controlling the Market, Microbiome Therapeutics Market to Grow By 32% CAGR through 2032, Says Fact.MR - GlobeNewswire
Improved Microbiome Sequencing Capabilities are Likely to Boost the Microbiome Therapeutics Market...
Looking Beyond C difficile: The Potential of the Gut Microbiome - Contagionlive.com
Dr. Elizabeth Garner speculates the FDA approval of RBX2660 for recurrent C difficile infection will pave the way for more restorative microbiome therapies.